Although implantation of crude bone marrow cells has been applied in a small number of patients for fracture healing, transplantation of peripheral blood CD34 + cells, the hematopoietic/endothelial progenitor cell-enriched population, in patients with fracture has never been reported. Here, we report the first case of tibial nonunion receiving autologous, granulocyte colony stimulating factor mobilized CD34 + cells accompanied with autologous bone grafting. No serious adverse event occurred, and the novel therapy performed 9 months after the primary operation resulted in bone union 3 months later without any symptoms including pain and gait disturbance.
INTRODUCTION
tionally been accomplished through complex vascular procedures or soft tissue transfers with adequate blood supply (8, 10, 21) . Whereas most fractures typically heal, a significant proportion (5-10%) of fractures fail to heal and result Recent progress in human embryonic and adult stem cell research has been reported in various fields, and in delayed union or persistent nonunion (17, 24) . Nonunion of the long bone is a common problem that can bone formation and regeneration has received much attention as a target for regenerative medicine because of be disabling. Treatment may require multiple operative procedures, prolonged hospitalization, and years of dis-the capacity of stem cells to self-renew and differentiate into various types of adult cells or tissues (1, 22, 28) . ability until a union is obtained or an amputation is performed. Among several factors resulting in this failure, Adult human peripheral blood (PB) CD34 + cells contain intensive endothelial progenitor cells (EPCs) as well as severe skeletal injuries consisting of fractures with a compromised blood supply have a high risk for leading hematopoietic stem cells (HSCs) (3). Tissue ischemia and cytokine mobilize EPCs from BM into PB, and mo-to either delayed unions or established nonunions. An essential requirement for healing such intractable frac-bilized EPCs specifically home to sites of nascent neovascularization and differentiate into mature endothelial tures is to restore the local blood flow, which has tradi-cells (vasculogenesis) (2, 25) . Therapeutic potential of for participating in a phase I/IIa clinical trial regarding transplantation of G-CSF mobilized CD34 + cells in pa-BM-derived CD34 + cells for neovascularization in hindlimb, myocardial, and cerebral ischemia has been dem-tients with nonunion. The clinical study protocol conformed to the Declaration of Helsinki and was approved onstrated in both preclinical and clinical studies (12,16). Interestingly, recent reports indicate that BM-derived by the ethics committees of the participating hospitals, Institute of Biomedical Research and Innovation (#08-CD34 + cells are capable of differentiating into osteogenic as well as hematopoietic and vasculogenic lineages 01) and Kobe University Hospital (#735). After the subject eligibility was confirmed, the patient was registered (4, 6, 7, 15, 26) . We and other groups reported that fracture induces mobilization of EPCs from BM into PB and in-as the first participant in the clinical trial. He received subcutaneous administration of G-CSF (5 µg/kg per day corporation of the circulating EPCs into the fracture site (13, 14, 19) . We first demonstrated that systemic infusion for 5 days) to mobilize EPCs from BM. Leukoapheresis (AS.TEC204; Fresenius HemoCare, Bad Homburg, Ger-of human circulating CD34 + cells into immunodeficient rats with nonhealing fracture contributes to morphologi-many) was performed to harvest PB mononuclear cells (MNCs) on day 5. The apheresis product number was cal and functional fracture healing by enhancing vasculogenesis and osteogenesis (18). In addition, we attempted 2.85 × 10 10 cells and the frequency of CD34 + cells in the apheresis product was 0.67% by fluorescence-activated local transplantation of CD34 + cells with atelocollagen gel, a bioabsorbable scaffold, in the same animal model cell sorting (FACS) analysis using CD34-specific monoclonal antibodies (Becton, Dickinson and Company, San and demonstrated the similar effect at the lower dose compared with the systemic administration (20). Con-Jose, CA). The apheresis product was kept at a concentration of 2 × 10 8 cells/ml in autoplasma at 4°C over-sidering the essential scarcity of EPCs in adult human, this preclinical outcome provided us with a realistic night (18 h) until the magnetic separation of CD34 + cells was started. CD34 + cells (1.30 × 10 8 ) were isolated by strategy for the future clinical application.
Based on these scientific evidences, we here report the CliniMACS system consisting of a CliniMACS Instrument, CD34 reagent, phosphate-buffered saline the first clinical case of tibial nonunion treated with autologous, granulocyte colony stimulating factor (G-CSF) (PBS)/EDTA buffer, and tubing set (Miltenyi Biotec, Bergisch Gladbach, Germany). Purity of the isolated mobilized CD34 + cells with atelocollagen scaffold immediately after the autologous bone grafting from iliac CD34 + cells was 92.5% by FACS analysis and the cell viability was 98.3%. The sorted CD34 + cells were also crest.
positive for the following endothelial lineage surface CASE REPORT markers: CD133, c-Kit, and CD31 (94.8%, 87.2%, and 99.3%, respectively). Immediately after the magnetic A 42-year-old male presented himself at our hospital complaining of tibial delayed union with pain at the cell sorting, a predefined dose (5 × 10 5 cells/kg) of CD34 + cells, which was determined by the preclinical fracture site and disability of life. He had had a closed tibial fracture and been treated by open reduction and study (20), was dissolved in 5 ml of atelocollagen gel (final concentration 1.5%) (KOKEN, Tokyo, Japan), internal fixation with plate fixation at another hospital 9 months before the initial presentation at our hospital.
which was used as a bioabsorbable scaffold for retaining the cells at the transplanted site. During the 9 months, fracture site failed to heal in spite of treating with low intensity pulsed ultrasound device Cell transplantation and bone grafting was performed under general anesthesia. Following refreshing fibrous [Sonic Accelerated Fracture Healing System (SAFHS), Teijin Ltd., Japan]. At the time of presentation, he com-tissue at the nonunion site and the surrounding cortical bone and grafting autologous cancellous bone from iliac plained of moderate pain and tenderness at the fracture site causing disability of weight-bearing gait. He was crest, CD34 + cells dissolved in atelocollagen gel were locally administered into the fracture site (bone defect clinically diagnosed as a nonunion according to the 1988 FDA Guidance Document Definition requiring 9 site) using an injection needle under fluoroscopic control (Fig. 2) . Replacement of the original plate was not per-months' duration of the nonunited fracture with no evidence of progressive healing over the previous 3 months formed because of no apparent instability at the fracture site and absence of radiolucency around screws.
(27). Anteroposterior and lateral radiographs led to diagnosis of noninfected bone defect type nonunion showing
The patient was allowed to gait with partial weight bearing at 6 weeks and with full weight bearing at 12 no bridging of four cortical sides. The radiographs also revealed no apparent instability at the fracture site and weeks after the operation. Twelve weeks after the treatment, the patient had no pain complaint with full absence of radiolucency around screws. The radiological findings were supported by three-dimensional (3D) weight-bearing gait. Anteroposterior and lateral radiograph provided diagnosis of achieved union showing the computed tomography (CT) (Fig. 1) .
We obtained an informed consent from the patient bony bridging in three of four cortical sides. 3D-CT also supported the radiographical findings ( Fig. 3 ). Taken to-koapheresis were frequent during the 12-week follow up. Safety, feasibility, and efficacy of this cell-based gether, the patient met the criteria of radiographical and clinical union as the primary end point in this treatment therapy in patients with nonunion/delayed union would be evaluated after completing this phase I/IIa clinical at 12 weeks. Six months after the treatment, the patient had no symptoms relating to the fracture and the com-trial. Several research groups have demonstrated the use-bined therapy of cell transplantation and bone grafting. He could gait with full weight bearing. No serious ad-fulness of local transplantation of total BM cells for fracture healing (5, 9) . Hernigou et al. reported that in verse events relating to G-CSF administration, leukoapheresis, and cell transplantation occurred during the 88% of patients with noninfected nonunions of the tibia, bone union was achieved by percutaneous grafting of observation period.
autologous total BM cells accompanied with the external DISCUSSION fixation or cast immobilization (9). Quarto et al. are the first to report the clinical effectiveness and usefulness To the best of our knowledge, this is the first clinical report of transplantation of autologous, G-CSF mobi-of BM mesenchymal stem cells (MSCs) associated to a porous ceramic for large long-bone defects (23) . Com-lized, and purified CD34 + cells in a patient with tibial nonunion. The cell therapy combined with autologous pared with transplantation of purified CD34 + cells, crude BM cell or BMMSC therapy does not require the time iliac bone grafting successfully achieved bone union, which was confirmed by clinical symptoms, radiograph, and cost for magnetic cell sorting. However, our group recently reported that intramyocardial transplantation of and 3D-CT as early as 3 months after the treatment. As for the safety evaluation in the first case, there were no human G-CSF mobilized total MNCs represents a possible risk of severe hemorrhagic myocardial infarction serious adverse events for which a causal relationship to the cell therapy could not be denied. In a recent clinical through the excessive inflammation induced by abundant infiltration of hematopoietic cells (11). Infusion of trial in our institution using autologous, G-CSF mobilized CD34 + cells in 17 patients with critical limb ische-the crude BM cells might cause similarly unfavorable event in the case of fracture. Further preclinical/clinical mia (12), no serious adverse events occurred although mild to moderate events relating to G-CSF and leu-studies would be warranted to compare the feasibility, 
